Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — Investor Presentation (January 2025)
27 slides from Scienture's investor presentation, Jan 8, 2025
Slide 1: Scienture Holdings, Inc.
i} Scienture Holdings, Inc. Prioritizing Patients. Improving Outcomes. NASDAQ; SCNX pnt 102 Smetolng, he. Ai Reened, ~ Plates ares
Slide 2: Safe Harbor Statement
Safe Harbor Statement The information st frth herein contains forward-looking statements within the feral securities laws, ineling the sae harbor provisions ofthe Private Series Litigation Reform Act of 1998, Forvard-looking statements nce al tatemens that do not relate solely o historical or curren
Slide 3: Scienture Holdings, Inc. | About Us
Scienture Holdings, Inc.| About Us We are a comprehensive pharmaceutical product group focused on providing enhanced value to the healthcare community by offering novel specialty across therapeutic areas, indications catering to different market segments and channels. Enhanced Value Addressing under
Slide 4: Our Vision
Our Vision A healthier world where the burden of disease is lightened through accessible and affordable, tailored therapies Our Values & How We Operate 8 Shaping Our World Together Our True North is guided by prioritizing Our goals and strategies are grounded Engagement and fellowship with our the n
Slide 5: Our Mission
Our Mission Our mission is to bring patients selectively designed drug product innovations by channeling the power of R&D through accelerated, nuanced commercialization. Beginnings Our founders identified critical gaps in care—challenging treatment paradigms, safety and efficacy limitations, access,
Slide 6: Leadership
H i i i i i 3 a i t i 4 e 3 Leadership
Slide 7: Leadership
Leadership Executive Management Suren Ajjarapu Chairman of the Board ceo Mr. Ajjarapu has served ‘as Chairman of the Board, CEO and Secretary since the acquisition of TRXADE Group, Inc. Mr. Ajjarapu ‘obtained an MBA from the University of South Florida and is also a graduate of the Venture Capital a
Slide 8: Scienture, LLC
Scienture, LLC (a wholly owned subsidiary of Scienture Holdings, Inc.) Specialty Pharmaceuticals pnt 102 Smetolng, he. Ai Reened, ~ Plates ares
Slide 9: Our Approach
Our Approach
Slide 10: Scienture, LLC | Significant Growth Opportunity
Scienture, LLC | Significant Growth Opportunity A highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Strategic Partners » | Proven R&D and Performance Manu
Slide 11: Leadership
Leadership Executive Management Shankar Hariharan, Ph.D. Founder & CEO & Michele Rath Shreena Patel Rahul Surana, Ph.D., MBA Vice President, Regulatory Affairs SVP &CCO EVP &COO & Project Management pnt 102 Smetolng, he. Ai Reened, ~ Plates ares Scientific Advisory Board ond — Suneel Gupta Wantanee
Slide 12: Delivering Better | Improving today's medicines for a better tomorrow
Delivering Better” | Improving today’s medicines for a better tomorrow Scienture discovers and delivers selectively designed drug innovations that enhance the treatment experience. It all starts with the patient. pnt 102 Smetolng, he. Ai Reened, ~ Plates ares Scienture Cornerstones Discover We spark
Slide 13: Delivering Better | Improving today's medicines for a better tomorrow
Delivering Better™ | Improving today’s medicines for a better tomorrow We fuse our core capabilities to these cornerstones, delivering scientific and commercial solutions, addressing gaps in therapy treatment, and leading to better health outcomes. pnt 102 Smetolng, he. Ai Reened, ~ Plates ares Scie
Slide 14: Product Pipeline
Product Pipeline pnt 102 Smetolng, he. Ai Reened, ~ Plates ares
Slide 15: Product Portfolio
Product Portfolio* NDA/BLA Submission Timeline SCN-102 | CVS/Hypertension @ 9 Le Oct 2023 2025 Oral solution /suspension for geriatric /pediatric use Formulation Animal Development Studies Anticipated Launch Indication 93.2025 242026 SCN-104 | CNS/Pain @ o) Drug device combination for convenient sel
Slide 16: SCN-102 | Product Strategy and Status
SCN-102 | Product Strategy and Status Product Description Ready-to-use stable solution/suspension product for pediatric/geriatric use Therapeutic Area and Indication/Mechanism of Action ‘Therapeutic area: CVS (Hypertension/stroke) Current Market Landscapé + One of the highest prescribed molecules in
Slide 17: SCN-104 | Fixed Dose Injection Pen
SCN-104 | Fixed Dose Injection Pen Product Description SCN-104 is an easy to use, multi-dose pen based delivery system for self injection and increased convenience Therapeutic Area and Indication/Mechanism of Action ‘Therapeutic area: CNS (Migraine) Indicated for the acute treatment of migraine head
Slide 18: SCN-106 | Biosimilar Product
SCN-106 | Biosimilar Product Product Description IP Strategy SCN-106 is a Large Molecule Biosimilar for CV use + Potential process /formulation IP coverage ‘Therapeutic Area and Indication/Mechanism of Action Regulatory Path and Clinical Strategy ‘Therapeutic area: CVS (hospital based) Value Proposi
Slide 19: SCN-107 | Extended-Release Injection
SCN-107 | Extended-Release Injection Product Description IP Strategy SCN-107 is a microsphere based long-acting injection with immediate release component + Formulation/method of treatment IP coverage - Orange book listable patents + Patent pending; PCT application published (PCT/US2021/028718) ‘The
Slide 20: n c Ke) © oe © a [e) iI UO = © = =
n c Ke) 5 © oe © a [e) iI UO = © = = fo) re)
Slide 21: Commercial Operations | Framework for Implementation
Commercial Operations | Framework for Implementation Deployment of key Operations prepare us for optimal drug commercialization and GTM launch of our first product in Q1 2025 Build Operational Readiness Evaluate and deploy required commercial systems: Logistics 3PL, ERP platform. Establish data requ
Slide 22: Commercial Operations | Strategy & Execution
Commercial Operations | Strategy & Execution We developed our sound strategy and designed a robust coordinated commercial infrastructure with a highly experienced team and proven industry partners. Field Sales F2F + Virtual Promotion 7 Syne05 CSO + Top Decile and Regional Tiering + Targeting & Segme
Slide 23: Partnerships
Partnerships eonate:
Slide 24: Partnerships
Partnerships. Our approach to identifying and engaging partnership opportunities starts with alignment and focus on identified therapies and delivery systems Alignment on Focus Therapies and Desired Outcomes Assess and Mobilize Identify Potential Initiatives Partners We look forward to finding ways
Slide 25: Corporate News
Corporate News
Slide 26: Recent Press Releases
Scienture Holdings,Inc., fka TRxADE Health, Inc. | Recent Press Releases * Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025 https: / /finance. yvahoo.com/news/scienture-holdings-inc-announces-participation- 130500301. html * Scienture, LLC, a wholly owned subsidiary o
Slide 27: Thank you!
Thank you! 33} Scienture Prioritizing Patients. Improving Outcomes. scienture.com Gpret0 202 Srewetolrg, he. A ieee, ~ Prades tat
Scienture Holdings — Investor Presentation (January 2025) on 6ix